Neuromuscular

As part of NeurologyLive®'s Year in Review, we've compiled the most-read feature-length stories that appeared on the website in 2023.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 29, 2023.

Mind Moments®, a podcast from NeurologyLive®, brings you a review of 2023, with insights from Sharon Cohen, MD, FRCPC; Robert A. Hauser, MD, MBA; Alberto Espay, MD, PhD; Carolina Ferreira Atuesta, MD, MSc; and Natalie Goedeker, CPNP. [LISTEN TIME: minutes]

As part of NeurologyLive®'s Year in Review, take a look at our most-read news in neuromuscular disorders in 2023.

In 2023, these episodes of the Mind Moments® podcast got the most attention from listeners, with this list brought to you as part of NeurologyLive®'s Year in Review.

As part of NeurologyLive®'s Year in Review, take a look at our most-watched interviews with key opinion leaders in neuromuscular disorders in 2023.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network for the week ending December 23, 2023. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 22, 2023.

The chief medical officer of Acadia Pharmaceuticals provided commentary on a caregiver analysis assessing beneficial experiences with trofinetide in patients with Rett syndrome. [WATCH TIME: 4 minutes]

The senior vice president, global head of medical affairs, and chief medical officer at Acadia Pharmaceutical, gave an overview of LILAC-2, a long-term extension study assessing trofinetide (Daybue), the first approved therapy for Rett syndrome.

Dr Neelam Gupta highlights differences between recently approved complement inhibitors for treatment of myasthenia gravis.

A neuromuscular disorder specialist, Dr Neelam Goyal shares data with efgartigimod, a neonatal Fc receptor inhibitor, for treatment of myasthenia gravis.

The vice president of the Rare Disease Translational Center at the Jackson Laboratory discussed results from a recently published study reinforcing stathmin-2 as a potential therapeutic strategy for ALS. [WATCH TIME: 4 minutes]

Expert neurologist Dr Lewis discusses the ‘typical’ and CIDP variants, and the new criteria for the variants in the updated guidelines.

Dr Lewis gives a comprehensive overview of CIDP and describes the most common symptoms seen in patients.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network for the week ending December 16, 2023. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 15, 2023.

AOC 1044 was well-tolerated in healthy volunteers, delivering dose-dependent increases in PMO concentrations in skeletal muscle following administration.

The positive data report could potentially build on phase 2 study of Duchenne muscular dystrophy in which CAP-1002 met its primary end point.

The senior vice president, global head of medical affairs, and chief medical officer at Acadia Pharmaceutical, provided an overview of LILAC-2, a long-term, open-label study assessing the treatment benefits of trofinetide (Daybue). [WATCH TIME: 6 minutes]

The OneRF Ablation System follows the Evo cortical and sEEG electrode product lines, marking a significant step in NeuroOne's journey to offer innovative solutions for neurological conditions.

Dr Goyal discusses new and emerging mechanisms of action to treat myasthenia gravis.

A expert discusses atypical presentation of myasthenia gravis and importance of early diagnosis and treatment.

Pitolisant demonstrated a dose-dependent improvement in excessive daytime sleepiness and fatigue, with a safety profile that was consistent with previous studies. Additional data to be shared in early 2024.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network for the week ending December 9, 2023. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 8, 2023.

Catch up on any of the neurology news headlines you may have missed over the course of November 2023, compiled all into one place by the NeurologyLive® team.